Quang A Le1, Jason N Doctor2, Lori A Zoellner3, Norah C Feeny4. 1. Department of Pharmacy Administration and Practice, Western University of Health Sciences, 309 E. Second Street, Pomona, CA, 91766-1854, USA. qle@westernu.edu. 2. Sol Price School of Public Policy/Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, 90089, USA. 3. Department of Psychology/Center for Anxiety and Traumatic Stress, University of Washington, Seattle, WA, 98195-1525, USA. 4. Department of Psychological Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106-7123, USA.
Abstract
PURPOSE: Health outcomes may depend on which treatment is received, whether choice of treatment is given, and whether a received treatment is the preferred therapy. We examined the effects of these key factors on the EuroQol-5D (EQ-5D-3L) in patients with PTSD. METHODS:Two hundred patients aged 18-65 years with PTSD diagnosis enrolled in a doubly randomized preference trial (DRPT) examining treatment, choice of treatment, and treatment-preference effects of prolonged exposure therapy (PE) and pharmacotherapy with sertraline (SER) (clinicaltrials.gov Identifier: NCT00127673). We performed difference-in-difference analysis to estimate the treatment effects of prolonged exposure therapy (PE) as compared to pharmacotherapy with sertraline (SER), receipt of choice versus no-choice of treatment, and receipt of preferred versus non-preferred treatment on health-related quality-of-life (HRQOL) outcome using the EQ-5D-3L completed at baseline and 10-week post-treatment. RESULTS: The treatment effects of PE on the EQ-5D scores in overall patients and subgroup of patients who preferred PE were 0.150 (p = 0.025) and 0.223 (p < 0.001), respectively. The effects of treatment choice were 0.088 (p = 0.050) and 0.156 (p = 0.043) in overall patients and subgroup of patients received SER, respectively. The effects of treatment preference were 0.101 (p = 0.038) and 0.249 (p = 0.004) in overall patients and subgroup of patients SER, respectively. CONCLUSIONS: Overall, PE is associated with better improved HRQOL, especially in patients who prefer it. Independently, allowing patients to choose their preferred treatment resulted in better HRQOL than either assigning them a treatment or giving them a treatment that is not preferred.
RCT Entities:
PURPOSE: Health outcomes may depend on which treatment is received, whether choice of treatment is given, and whether a received treatment is the preferred therapy. We examined the effects of these key factors on the EuroQol-5D (EQ-5D-3L) in patients with PTSD. METHODS: Two hundred patients aged 18-65 years with PTSD diagnosis enrolled in a doubly randomized preference trial (DRPT) examining treatment, choice of treatment, and treatment-preference effects of prolonged exposure therapy (PE) and pharmacotherapy with sertraline (SER) (clinicaltrials.gov Identifier: NCT00127673). We performed difference-in-difference analysis to estimate the treatment effects of prolonged exposure therapy (PE) as compared to pharmacotherapy with sertraline (SER), receipt of choice versus no-choice of treatment, and receipt of preferred versus non-preferred treatment on health-related quality-of-life (HRQOL) outcome using the EQ-5D-3L completed at baseline and 10-week post-treatment. RESULTS: The treatment effects of PE on the EQ-5D scores in overall patients and subgroup of patients who preferred PE were 0.150 (p = 0.025) and 0.223 (p < 0.001), respectively. The effects of treatment choice were 0.088 (p = 0.050) and 0.156 (p = 0.043) in overall patients and subgroup of patients received SER, respectively. The effects of treatment preference were 0.101 (p = 0.038) and 0.249 (p = 0.004) in overall patients and subgroup of patientsSER, respectively. CONCLUSIONS: Overall, PE is associated with better improved HRQOL, especially in patients who prefer it. Independently, allowing patients to choose their preferred treatment resulted in better HRQOL than either assigning them a treatment or giving them a treatment that is not preferred.
Authors: C Stoll; G Schelling; A E Goetz; E Kilger; A Bayer; H P Kapfhammer; H B Rothenhäusler; E Kreuzer; B Reichart; K Peter Journal: J Thorac Cardiovasc Surg Date: 2000-09 Impact factor: 5.209
Authors: Mary R Janevic; Nancy K Janz; Julia A Dodge; Xihong Lin; Wenqin Pan; Brandy R Sinco; Noreen M Clark Journal: Soc Sci Med Date: 2003-04 Impact factor: 4.634
Authors: Jana Sommer; Jan Dyczmons; Sandra Grobosch; Veronika Gontscharuk; Markus Vomhof; Michael Roden; Andrea Icks Journal: BMJ Open Date: 2020-09-09 Impact factor: 2.692